Royalty Funds: How Accredited Investors Earn Income From Intellectual Property
Royalty Funds: Music, Pharma and Resource Royalties Explained | Angel Investors Network Royalty Funds: How Accredited Investors Earn Income From Intellectual Property By Jeff Barnes, MBA | Angel Inves
Royalty Funds: How Accredited Investors Earn Income From Intellectual Property
According to Alternatives Watch, Partners Group's royalty strategy grew 50% in six months to $1.5 billion in assets under management by mid-2026, closing eight deals that included a South Park royalty note. That kind of institutional sprint tells you something. Royalty funds are not a niche curiosity anymore. They represent a real income-generating asset class, and accredited investors who understand how they work can position themselves well before the market matures further. That said, I have spent enough time analyzing these funds to know the pitch usually sounds better than the reality. This article walks you through what royalty funds actually are, where the income comes from, and where your money can quietly disappear.
TL;DR: Royalty funds pay income from patents, music catalogs, drug licenses, or mineral extraction rights. They produce cash flows that move independently of the stock market. Pharmaceutical royalties (see Royalty Pharma's 15.8% ROIC in 2025) offer the most stable return history. Music royalties carry streaming-rate risk. Natural resource royalties track commodity prices. Fees of 1.5% management plus 15% carried interest consume a real slice of your income. Minimums typically start at $250,000. Know what you own before you write the check.
How Royalty Funds Work
A royalty is a contractual right to receive a percentage of revenue generated from an asset you do not operate. You do not build the mine. You do not run the drug trial. You do not manage the recording studio. You simply own a claim on a slice of the income that flows from someone else's activity.
Royalty funds pool capital from accredited investors and use it to buy these contractual rights at scale. The fund manager acquires royalties, collects payments over time, and distributes cash to investors after taking fees. The underlying assets produce income that is not tied to corporate earnings cycles or Federal Reserve rate decisions in the way bond or stock income is. That uncorrelated nature is the primary selling point.
There are three major categories: music and entertainment royalties, pharmaceutical royalties, and natural resource royalties. Each operates under different legal frameworks, different risk profiles, and different return expectations. Treating them as interchangeable is a mistake most investors make early and regret later.
Music Royalties: Hipgnosis, Round Hill, and Royalty Exchange
Music royalties come in several forms: master recording royalties (income when a song is streamed or used commercially), publishing royalties (income from the underlying composition), and synchronization royalties (income when a song appears in a film, advertisement, or video game). A fund acquires catalogs or individual song rights, then collects every time those songs generate revenue.
Hipgnosis Songs Fund became the most prominent name in this space. The fund acquired catalogs from artists including Neil Young, Blondie, and Shakira, accumulating a portfolio of more than 65,000 songs. The pitch was straightforward: hit songs are evergreen assets. "Mr. Brightside" by The Killers has streamed billions of times without end in sight. The income feels predictable.
The reality proved more complicated. Hipgnosis faced governance controversies and valuation disputes that depressed its share price well below net asset value. Round Hill Music Royalty Fund encountered similar discount-to-NAV problems before eventually being taken private. The public market structure for music royalties did not perform as advertised for many investors who bought in expecting stable income.
Royalty Exchange operates differently. It functions as a marketplace where you can buy individual royalty streams, sometimes for as little as a few thousand dollars. The yields on offer look attractive, often in the 7% to 12% range, but the income depends entirely on continued commercial use of specific songs. A catalog that seems durable can see streams fall sharply if a single playlist algorithm changes.
The core risk here is streaming rate risk. Spotify, Apple Music, and other platforms set the per-stream payout rate, and they have consistently pushed those rates down over time. If you own the right to 10% of streaming income from an album, and the per-stream rate drops 20%, your income drops 20% regardless of how many times the songs are streamed. That is a risk the fund prospectus will mention but not emphasize.
For more on how private income-generating assets compare, see our overview of private credit funds for accredited investors.
Pharmaceutical Royalties: Royalty Pharma and the Stability Case
Pharmaceutical royalties operate on a different logic. A university or biotech company invents a drug, licenses it to a large pharmaceutical manufacturer, and collects a royalty on every prescription filled. Royalty Pharma (RPRX) buys those royalty streams from the original inventors or licensors, providing them with upfront capital in exchange for the ongoing income.
The numbers from Royalty Pharma's 2025 results are worth examining closely. Royalty Pharma reported royalty receipts of $3.13 billion in 2025, up 13% from the prior year. Portfolio receipts reached $3.25 billion, a 16% increase. Return on invested capital came in at 15.8%. Return on invested equity reached 22.8%.
More telling than the raw returns is the consistency. According to RPRX's Q4 2025 earnings presentation, the company's ROIC standard deviation has been just plus or minus 1.2% since its IPO. ROIE standard deviation sits at plus or minus 1.8%. That is among the tightest return distributions in the alternatives space. Most asset classes you consider alternatives do not come close to that kind of stability.
The reason is structural. Drug royalties are embedded in long-term licensing agreements. The royalty on a blockbuster drug like Imbruvica or Trikafta does not reset every quarter based on market sentiment. It pays based on prescriptions filled. Unless the drug gets pulled from the market or a superior treatment emerges, the cash flow continues.
DRI Healthcare is another publicly traded royalty fund that focuses specifically on late-stage pharmaceutical assets. It operates on the same basic model: acquire royalty interests from academic institutions and smaller biotechs that need capital before their drug reaches peak commercial potential.
The main risk in pharmaceutical royalties is patent expiration. Every drug royalty has a defined legal life. When the patent expires, generic competition enters, sales drop sharply, and the royalty stream shrinks or disappears. A fund concentrated in drugs with near-term patent cliffs faces a real income reduction even if its management team performs exactly as planned.
Natural Resource Royalties: Franco-Nevada and Wheaton Precious Metals
Natural resource royalties work through a different mechanism called a streaming agreement. Franco-Nevada and Wheaton Precious Metals are the two most established names in this category. They provide upfront capital to mining companies in exchange for the right to purchase a percentage of future gold, silver, or other metal production at a fixed, below-market price.
Franco-Nevada, for example, holds royalties on over 400 properties across the Americas, Africa, and Australia. When gold trades at $2,500 per ounce and Franco-Nevada's streaming agreement lets it buy gold at $400 per ounce, the margin is substantial. The mining company accepts this arrangement because it needs capital to build or expand a mine without diluting equity or taking on more debt.
Oil and gas royalties follow a similar structure. Montego Minerals is raising its fifth royalty fund targeting $50 million, focused on zero-use oil and gas royalties with production lives of 35 years or more. The fund structure offers quarterly distributions and liquidity after year three. That liquidity runway is worth noting. Most royalty funds are illiquid for several years after you invest.
The primary risk in natural resources is commodity price exposure. Franco-Nevada's income rises and falls with gold prices. Wheaton Precious Metals moves with silver. An oil and gas royalty fund tracks crude prices. If you believe natural resource royalties offer uncorrelated income, you need to define what you mean by uncorrelated. They are uncorrelated to software company earnings. They are not uncorrelated to the price of gold or oil, and those prices can move dramatically in either direction.
Our article on adding commodity exposure through alternatives covers the broader case for and against this approach.
The Fee Problem: How Much Income Do Fees Actually Consume?
This is where the royalty fund pitch gets uncomfortable, and I want to be direct about it.
The Lincoln Financial and Partners Group evergreen royalty fund, launched in September 2025, targets 8% to 12% annualized returns. The fee structure is 1.5% annual management fee plus a 15% performance allocation above a hurdle rate. The minimum investment is $250,000.
Run the math on that. If the fund delivers 10% gross returns, the 1.5% management fee drops your net to 8.5% before the performance fee. If the performance allocation applies to the full 8.5%, you give back another 1.275%. Your net return lands around 7.2%. That is still meaningful income, but you started with a 10% gross return and ended with 7.2%. The fund manager captured nearly 30% of your income through fees.
Compare that to a direct investment in RPRX stock. You pay standard brokerage commissions. You get exposure to Royalty Pharma's 15.8% ROIC without a 1.5% drag sitting on top. The trade-off is that you own a single company rather than a diversified portfolio of royalty streams, but the fee comparison matters when you evaluate whether the diversification justifies the cost.
Some funds also carry redemption gates, meaning you cannot withdraw capital whenever you choose. The Partners Group structure allows periodic liquidity windows, but the fund can suspend redemptions if market conditions deteriorate. You should read that provision carefully before you commit capital. Illiquidity risk is real, and fees compound on capital you cannot easily exit.
Correlation to Other Asset Classes
The uncorrelated income argument is real, but nuanced. Pharmaceutical royalties have the strongest case for true decorrelation. Drug prescriptions do not drop when the S&P 500 falls 20%. Cancer patients still fill their Trikafta prescriptions during a market correction. The income stream from a drug royalty is tied to patient populations, prescribing patterns, and patent timelines, not investor sentiment.
Music royalties are more complicated. Streaming consumption did not collapse during the 2020 COVID downturn. It actually increased. But the commercial synchronization market, where songs get licensed for advertisements and films, shrinks when ad budgets contract. A fund with heavy synchronization exposure behaved differently than one focused on streaming income during that period.
Natural resource royalties carry meaningful correlation to broader commodity cycles, which often correlate with inflation expectations and global economic growth. During the 2022 inflation spike, gold royalty companies performed well. During the 2023 growth slowdown, they pulled back. Calling that truly uncorrelated to equities requires some selective memory about which periods you measure.
The honest summary is that royalty funds reduce your correlation to equities, but they do not eliminate it. They introduce different correlations instead. Understanding those specific correlations matters more than accepting the blanket "uncorrelated income" pitch at face value.
For a broader discussion of how alternative income streams fit into a portfolio, see our guide on building an alternative investment portfolio.
Royalty Fund Comparison: Music vs. Pharma vs. Natural Resources
| Category | Target Yield | Primary Risk | Liquidity | Typical Minimum |
|---|---|---|---|---|
| Music Royalties (Royalty Exchange, Hipgnosis) | 7% to 12% | Streaming rate cuts / catalog depreciation / platform risk | Low to moderate. Public funds trade at NAV discounts. Private funds locked 2 to 5 years | $5,000 to $100,000 (Royalty Exchange) / $250,000+ (institutional funds) |
| Pharmaceutical Royalties (RPRX, DRI Healthcare) | 8% to 16% ROIC (RPRX 15.8% in 2025) | Patent expiration / single-drug concentration / generic entry | RPRX trades publicly (daily liquidity). Private funds locked 3 to 7 years | Public: no minimum (buy RPRX shares). Private funds: $250,000+ |
| Natural Resource Royalties (Franco-Nevada, Montego) | 6% to 10% distribution yield | Commodity price swings / mine production delays / political risk in emerging markets | Franco-Nevada trades publicly. Montego Fund 5 liquidity after year 3 | Public: no minimum. Private funds: $50,000 to $250,000 |
Risk Factors You Need to Understand Before You Invest
Royalty stream concentration. A fund that derives 40% of its income from three drug royalties or two song catalogs carries significant concentration risk. If any single royalty underperforms, the income impact on your distribution is large. Ask fund managers for their top-10 royalty exposure before committing capital.
Streaming rate risk. Spotify's per-stream rate dropped from approximately $0.0035 in 2020 to $0.003 in 2024. That 14% compression directly reduces income for music royalty holders. The streaming platforms hold pricing power, not the rights holders. This dynamic does not improve over time as platforms scale.
Term expiration. Every royalty has an end date. Drug patents expire. Music copyrights eventually enter the public domain under certain statutory timeframes (though U.S. copyright terms for sound recordings extend 95 to 110 years for works from the late 20th century, so this is less immediately pressing for music). Oil and gas reserves deplete. A fund manager who acquires royalties near the end of their term at high valuations will deliver disappointing returns. Understand the weighted average remaining term of any fund's royalty portfolio before you invest.
Valuation opacity. Private royalty funds mark their portfolios using discounted cash flow models. Those models require assumptions about future income, discount rates, and asset longevity. Two managers can look at the same royalty and value it 30% differently. The NAV you see on a quarterly statement is an estimate, not a market price.
Your Next Step
If you want direct pharmaceutical royalty exposure with daily liquidity, start by reading Royalty Pharma's full-year 2025 results and their most recent 10-K. Understand what drugs are in the portfolio and when those patents expire. That gives you a concrete foundation for evaluating the investment on its actual merits.
If you want fund-level diversification across royalty types, request the fee disclosure document, the top-10 royalty concentration report, and the weighted average remaining term from any manager you consider. If they cannot provide those three data points clearly, walk away. Good managers know their portfolios at that level of detail. Evasive answers on concentration and term are red flags worth taking seriously.
Royalty funds can deliver what they promise. The income is real. The decorrelation from equities is real, within limits. The fee drag and the concentration risk are equally real. Your job is to find a fund where the first two outweigh the second two by a margin wide enough to justify the illiquidity.
Author Disclosure: Jeff Barnes, MBA has no personal position in any company, fund, or platform named in this article. Angel Investors Network has no current commercial relationship with any party mentioned. AIN provides marketing and education services, not investment advice. Past performance does not guarantee future results. All investments involve risk, including loss of principal.
Topics
Looking for investors?
Browse our directory of 750+ angel investor groups, VCs, and accelerators across the United States.
About the Author
Jeff Barnes, MBA
Continue Reading
Tikehau Capital Closes €5.2 Billion European Direct Lending Fund — 60% Bigger Than Prior Vintage
Tax Lien Certificates: The Government-Backed Alternative Investment Most Investors Ignore
Water Infrastructure Funds: Why Smart Money Is Treating Water as the New Oil
Goldman Sachs PE Acquires AEGIS Hedging: What Commodity Risk Infrastructure Means for Private Investors
Wellington, Vanguard, and Blackstone Launch WVB Funds: What Interval Funds Mean for Your Portfolio
